dc.contributor.author | Patel, V | |
dc.contributor.author | Efimov, A | |
dc.contributor.author | Baker, D | |
dc.contributor.author | Kang, AS | |
dc.date.accessioned | 2021-06-25T14:10:13Z | |
dc.date.available | 2021-06-25T14:10:13Z | |
dc.date.issued | 2021-06-11 | |
dc.identifier.citation | Patel, Visha et al. ‘Immunogenicity of Biologics Used in the Treatment of Moderate to Severe Psoriasis’.2 July 2021 : 171 – 178. | |
dc.identifier.issn | 1093-2607 | |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/72726 | |
dc.description.abstract | The number of biologic drugs available for the treatment of psoriasis continue to expand. However, being biological proteins and thus potentially immunogenic, there is evidence that anti-drug-antibodies develop against the various therapeutic proteins currently being utilised. Although chimeric antibodies that contain elements of the parental monoclonal antibodies are immunogenic, anti-drug antibodies occur even if the biologic is a fully human protein and these can impact on clinical efficacy and safety. However, there is a wide variation in the reported level of anti-drug-antibodies for the same and different treatments that is highlighting issues with various assays used in anti-drug antibody detection. Here we review the available data on the occurrence of anti-drug antibodies in people with psoriasis treated with biologic agents | en_US |
dc.format.extent | 171 – 178 | |
dc.publisher | IOS Press | en_US |
dc.relation.ispartof | Human Antibodies | |
dc.rights | © The authors, 2021. The definitive, peer reviewed and edited version of this article is published in Human Antibodies, vol. 29, no. 3, pp. 171-178, 2021.
The final publication is available at IOS Press through http://dx.doi.org/10.3233/HAB-210447 | |
dc.title | Immunogenicity of biologics used in the treatment of moderate to severe psoriasis | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.3233/hab-210447 | |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |